Key Highlights

  • Merck shares rose 1.33% to $134.58, against a prior close of $132.81.
  • Sacituzumab tirumotecan met its overall survival endpoint in TroFuse-015.
  • The trial missed its secondary progression-free survival endpoint.
  • The Dividend was raised to $0.88.
  • The consensus target is about $155.74.

Positive TroFuse-015 Readout Powers a Rebound

Merck (NYSE:MRK) shares rose 1.33% to $134.58 on Friday, on Volume of about 6.24 million shares, rebounding from a sharp pullback earlier in the week. Investors weighed positive Phase 3 TroFuse-015 data against the discontinuation of the nemtabrutinib program.

Sacituzumab tirumotecan, a TROP2 antibody-drug conjugate, met its overall survival endpoint in third-line-or-later gastroesophageal adenocarcinoma. It missed the secondary progression-free survival endpoint and showed no new safety signals.

Second Positive Phase 3 Readout Follows the BELLWAVE Halt

The readout is the second positive Phase 3 result in the TroFuse program. It follows the Nov. 17 halt of the BELLWAVE program, which the stock had sold off on.

Other context includes a new AI drug-discovery collaboration with Isomorphic Labs, a dividend raised to $0.88 and a German court lifting the injunction on subcutaneous Keytruda.

Valuation and Pharma Peers Mixed

Merck trades at about 16.01 times forward Earnings and 138.77 times trailing earnings, on Earnings Per Share of $3.21. The Dividend Yield is 2.53%, and the stock sits below its 50-day average of roughly $145. The consensus rating is Moderate Buy with an average target of about $155.74.

Pharma peers were mixed. Johnson & Johnson (NYSE:JNJ) rose 1.19%, Eli Lilly (NYSE:LLY) added 0.09%, AbbVie (NYSE:ABBV) gained 1.68% and Pfizer (NYSE:PFE) edged down 0.05%.

More TroFuse Data and Pipeline Updates Are the Next Catalysts

Merck's rebound reflects positive oncology data after a setback earlier in the week. Investors will watch further TroFuse readouts and the effect of the BELLWAVE discontinuation on the hematology pipeline.